Nello Mainolfi, Chief Executive Officer at Kymera Therapeutics, Inc. (KYMR), sold 30,000 shares at $80.74 ($2.4M) on 2026-04-29, disclosed to the SEC on 2026-04-29.
Scheduled sale ($2.4M) by Chief Executive Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $80.74 | 17,005 | $1.4M | 56.4% |
| 2 | $81.70 | 12,059 | $985K | 40.5% |
| 3 | $82.45 | 936 | $77K | 3.2% |
| Total | $81.18 avg | 30,000 | $2.4M | 100% |
| Filing → |
| KYMR | SELL | 2026-07-02 | $9.2M | — | Filing → |
| KYMR | SELL | 2026-02-25 | $2.7M | — | Filing → |
| KYMR | SELL | 2025-12-31 | $4.7M | — | Filing → |